GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 130
- Registration Number
- NCT06154837
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT06113198
- Locations
- π°π·
GSK Investigational Site, Seoul, Korea, Republic of
Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT06104319
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 282
- Registration Number
- NCT06079190
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT06077877
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
Concentration-QT Study of Paroxetine in Healthy Adults
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT06065735
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
- Conditions
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 360
- Registration Number
- NCT06062420
- Locations
- πΉπ·
GSK Investigational Site, Izmir, Turkey
A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT06058390
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT06041386
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks
- Conditions
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2000
- Registration Number
- NCT06025695
- Locations
- π¨π³
GSK Investigational Site, Wenshan, China